Evotec Se · XETR:EVT
Evotec — Investor Presentation (October 2025)
29 slides from Evotec's investor presentation, October 2025
Slide 1: General company presentation
General company presentation Scientific Operational Excellence Excellence Evotec SE, Company presentation, October 2025
Slide 2: Disclaimer
Disclaimer This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the “Company”, “we,” “our” or “us”). This presentation is made pursuant to Sec
Slide 3: Pioneering Drug Discovery / Financials
1 Pioneering Drug Discovery 2 Financials PAGE 3
Slide 4: About us
Pioneering Drug Discovery About us Pioneering Drug Discovery Just – Evotec Biologics –better Pioneering drug discovery and development, leveraging cutting-edge monetization of technology & assets technology, disruptive science, and AI-driven innovation. Together with World leader in developing enabl
Slide 5: New strategy – sharpened investment focus
New strategy – sharpened investment focus Building blocks for value creation Enabling partners through technology and science leadership Discovery & Preclinical Development Just – Evotec Biologics • Target Identification to IND • World leader in developing enabling technologies for end-to-end contin
Slide 6: Strategy in Execution – simplifying our business model
Strategy in Execution – simplifying our business model Implementation has started Strategic shift Focus & Action Streamlining • Cleaned up portfolio - high quality, high potential assets – divested EVT 201 asset pipeline • Own asset development limited to proof points for technological innovation Op
Slide 7: Operating in highly attractive markets
Operating in highly attractive markets Outsourcing and paradigm shift as drivers for superior growth Global R&D spend Outsourcing share $ 260 bn • Global R&D spend with 3% growth 2023-2030 5-7% 40% Clinical 15% • Outsourcing trend continuing - drug discovery catching up CAGR (addressable CRO market
Slide 8: Funding stabilizing – Early-stage R&D to catch up
Funding stabilizing – Early-stage R&D to catch up Key trends in VC market VC funding back to pre-pandemic levels Discovery & Pre-Clinical vs. Clinical not in sync US$ m 25.000 75% 20.000 15.000 50% 10.000 5.000 0 25% Q4 2020 Q4 2024 Q3 2021 Q4 2021 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1
Slide 9: Next-generation technology improving R&D returns
Next-generation technology improving R&D returns Benefits of better prediction Step change required to produce faster, safer & better R&D outcomes $ 7.7 bn Prediction, automation, spend of TOP 20 industrialisation, AI are key Pharma on clinical trials that were terminated in 2024 Evotec leading in t
Slide 10: Growing faster than market with premium offerings
Growing faster than market with premium offerings Leading technology as drivers for superior growth Multi-Omics Market Biologics CDMO market USD bn USD bn Drivers for outperformance 15 40 30 10 >20% >10% Base market growth (“CRO essentials”) 5-7% 20 5 (Tipping point to be monitored) 10 0 0 + additio
Slide 11: Enhancing our commercial model
Enhancing our commercial model Targeted value proposition Our offerings Our value proposition Our commercial position 3 • Access to cutting edge technology, next-gen biology & AI Pioneering drug • Enhance drug discovery & development program Strategic partnerships & discovery & risk/ rewards sharing
Slide 12: Asset pipeline with ~€16 bn opportunity (non-risk adjusted)
Asset pipeline with ~ € 16 bn opportunity (non-risk adjusted) Re-prioritized asset pipeline an important value creation lever Pipeline priorities & targets Existing portfolio with long-term revenue upside Non-risk adjusted revenue, in € bn, excluding new pipeline building • Investments into a unique
Slide 13: Just Evotec Biologics - better monetisation of technology & assets
Just Evotec Biologics - better monetisation of technology & assets Improving operational efficiency by focusing on technology leadership and core competencies Just – Evotec Biologics today Our vision for tomorrow Intellectual Expand leadership on core technology Validated technology leadership prope
Slide 14: Levers of value creation
Levers of value creation Above market growth rates at better-quality earnings Technological leadership and innovation; steering portfolio towards high value segments Commitment to Operational Excellence > € 50 m cost reduction by 2028 & further productivity improvement Just – Evotec Biologics –bette
Slide 15: Financials
1 Pioneering Drug Discovery 2 Financials PAGE 15
Slide 16: FY 2024: Navigating a challenging year – JEB revenue +71%
FY 2024: Navigating a challenging year – JEB revenue +71% Condensed income statement FY 2024 in € m1 FY 2024 FY 2023 Change Comments External Revenues 797.0 781.4 2% Soft Shared R&D market; temporarily more investments in late-stage assets Shared R&D 611.4 673.0 (9)% Strong growth momentum of JEB ba
Slide 17: D&PD behind expectations – JEB ahead of plan
D&PD behind expectations – JEB ahead of plan Condensed income statement H1 2025 in € m1 H1 2025 H1 2024 Change Comments External Revenues 371.2 390.8 (5)% Behind initial group expectations D&PD 269.0 302.4 (11)% No recovery of relevant market, yet JEB2 102.2 88.5 16% Broadening customer base Gross m
Slide 18: Improved Operating and Investing cash flow vs. H1 2024
Improved Operating and Investing cash flow vs. H1 2024 Quarterly Cash Flows Q1 ‘24 Q2 ‘24 Q3 ‘24 Q4 ‘24 Q1 ‘25 Q2 ‘25 • Improved Operating Cash flow (OCF) Quarterly 91.1 Favorable changes in Cash flows, working capital in € m 16.7 74,2 • Reduced cash outflow 4.6 from investing activities 42,6 16,9
Slide 19: Liquidity developing as expected
Liquidity developing as expected Quarterly liquidity development Net debt, in € m 173 164 43 107 114 • Stable financing, materialized cost 397 savings and proactive liquidity Liquidity at management 371 quarter end, 348 in € m • Total liabilities and lease 299 303 obligations decreased to € 462 m fr
Slide 20: Cost out initiatives ahead of plan
Cost out initiatives ahead of plan Cost reduction measures Impact ~ 600 FTE reduction in D&PD Measure Progress (Mar 24 – Jun 25); +200 FTE vs. Priority Reset Target • Remaining Priority Reset initiatives implemented • Disciplined spending & restricted hiring activities FY 2025 total cost-out target
Slide 21: Guidance 2025
Guidance 2025 FY 2024 Guidance 20251 Comment Stable development driven by strong JEB segment; Drug Discovery & Group revenues € 797 m € 760 - 800 m Development in soft market environment pivoting towards high- value offering Further prioritisation of scalable R&D expenditure2 € 50 m € 40 - 50 m tech
Slide 22: Commitment to operational excellence >€50 m
Commitment to operational excellence Creating a sustainable cost base long-term Key levers to be addressed (short to mid-term) COGS Structural cost reset, overcapacity, footprint and processes SG&A Reduce complexity, standardisation, from admin to >€ 50 m business value Total cost out by 2028, produ
Slide 23: Mid-term Outlook
Mid-term Outlook 2028 aspiration Revenue Adj. EBITDA CAGR1 margin 2024-2028 2028 8-12% >20% (FY 2024: € 797 m) (FY 2024: ~3%) Drivers Market recovery, Operating leverage, Differentiation, Mix/Value add-ons, Value add-ons Productivity, Cost optimisation PAGE 23 1 CAGR = Compound annual growth rate
Slide 24: Appendix
Appendix PAGE 24
Slide 25: Experienced management team with long-term mission
Experienced management team with long-term mission The management team Experience Experience • 2017 – 2022 CEO of Mediq • 2018 – 2024: • 2005 – 2017 Various CFO of Mediq leadership positions at Linde • 2016 – 2017: Group, since 2007 member CFO of GE Mining of the Group Executive • 2001 – 2016: Commi
Slide 26: Global view and deep experience for best governance
Global view and deep experience for best governance Independent and diverse Supervisory Board • Since 2014 Member of • Since 2019 Member of the • Since 2022 Member of Evotec’s Evotec’s Supervisory Board Supervisory Board Supervisory Board (2021 Chairperson) (2021 Vice Chairperson) • Since 2013, Diff
Slide 27: Sustainability at Evotec
Sustainable growth enabled by commitment, culture, values & people Sustainability at Evotec Our People Our Partners Safe work environment High governance standards and effective structures Diversity, equity, and inclusion Stakeholders‘ engagement Animal welfare and bioethics Our Patients Our Values
Slide 28: Shareholders supporting sustainable growth
Shareholders supporting sustainable growth Shareholder structure1 ~ 8% Novo Holdings A/S ~ 7% Mubadala Investment Company ~ 10% Triton GP HoldCo SARL ~ 75% Free float Number of shares: Listings: 52 week high/low: 177.8 m Frankfurt Stock Exchange (SDAX, TecDAX), Ticker: EVT € 10.62/€ 5.06 NASDAQ Glob
Slide 29: Volker Braun, Investor Relations & ESG
Volker Braun EVP Global Head of Investor Relations & ESG +49 (0) 40 228 999 338 (direct) +49 (0) 151 1940 5058 (mobile) [email protected]